A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Launched by THERAVECTYS S.A. · Mar 13, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new treatment called Lenti-HPV-07 for patients with cervical or oropharyngeal cancer caused by the Human Papilloma Virus (HPV). The main goals are to find out if Lenti-HPV-07 is safe to use and whether it can help the body fight the cancer by triggering an immune response. Participants will be placed in one of two groups based on their cancer type: those with recurrent or advanced cancer and those who are newly diagnosed with locally advanced cancer.
To participate, individuals must have confirmed HPV-related cancer and be in good overall health, with no serious infections like HIV or hepatitis. During the trial, participants will receive the study treatment and will be followed for up to one year to monitor their health through clinic visits or phone calls. This is an important opportunity to explore a new potential treatment for HPV-related cancers, and the study is currently looking for volunteers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • histologically confirmed invasive HPV-related oropharyngeal or cervical cancer
- • ECOG performance status of 0 or 1
- • adequate hepatic, renal, pulmonary, and bone marrow/hematological function
- Exclusion Criteria:
- • - with seropositivity for HIV, active hepatitis C virus (HCV) infection, or hepatitis B (HBV) infection
About Theravectys S.A.
Theravectys S.A. is an innovative biotechnology company dedicated to developing advanced therapeutic solutions for the treatment of viral infections and cancer. With a strong focus on harnessing the potential of proprietary viral vector technology, Theravectys aims to create targeted and effective therapies that improve patient outcomes. The company is committed to rigorous clinical research and development, collaborating with leading scientific institutions and regulatory bodies to ensure the safety and efficacy of its clinical trials. Through its pioneering approaches, Theravectys strives to address unmet medical needs and contribute to the advancement of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Tampa, Florida, United States
Tulsa, Oklahoma, United States
Orlando, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported